SARS-CoV-2 disease (COVID-19) is an emerging disease of global concern due to clinical,
social, economic and public health impact. As the pandemic spread, it was seen that …

We read with interest the study by Lynn et al. among 402 hospitalized COVID-19 patients,
which did not show any survival benefit in those who were administered therapeutic dosage …

There were initially three clear lines of evidence in support of an association between
thrombosis and coronavirus disease 2019 (COVID-19), as caused by SARS-CoV-2 (severe …

The exceptional outbreak of COVID-19 pandemic has let the scientific community to work
closely and quickly learnt things in a very short period of time. This has let us recognize that …

Coronavirus disease 2019 (COVID-19) is a systemic disease that can be life-threatening
involving immune and inflammatory responses, and that can result in potentially lethal …

Rising incidence of thromboembolism secondary to COVID-19 has become a global
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …

Introduction The outcomes related to different anticoagulation doses in Coronavirus disease
2019 (COVID-19) patients are not well established. COVID-19 is associated with increased …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked
to a higher risk of mortality compared to influenza, which is mainly due to severe secondary …

Thrombosis is common in patients with coronavirus disease 2019 (COVID-19)-associated
moderate illness. A systematic review and meta-analysis reported venous thromboembolism …

The coronavirus disease 2019 (COVID-19) shows high incidence of thromboembolic events
in humans. In the present study, we aimed to evaluate if anticoagulation prior to COVID-19 …